Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Meribank Biotech Co's enterprise value is NT$1,738.3 Mil.
Meribank Biotech Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$44.1 Mil. Therefore, Meribank Biotech Co's EV-to-EBITDA for today is 39.40.
The historical rank and industry rank for Meribank Biotech Co's EV-to-EBITDA or its related term are showing as below:
ROCO:4724'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -428.97 Med: -22.6 Max: 39.4
Current: 39.4
During the past 8 years, the highest EV-to-EBITDA of Meribank Biotech Co was 39.40. The lowest was -428.97. And the median was -22.60.
ROCO:4724's EV-to-EBITDA is ranked worse than 77.72% of 404
companies
in the Biotechnology industry
Industry Median: 13.02
vs ROCO:4724: 39.40
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Meribank Biotech Co (ROCO:4724) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Meribank Biotech Co's PE Ratio (TTM) for today is calculated as:
Meribank Biotech Co's share price for today is NT$8.95.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Meribank Biotech Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was NT$-1.430.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Meribank Biotech Co's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4724 vs VRTX, REGN, MRNA: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Meribank Biotech Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Meribank Biotech Co EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Meribank Biotech Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Meribank Biotech Co's EV-to-EBITDA falls into.
Meribank Biotech Co's current Enterprise Value is NT$1,738.3 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Meribank Biotech Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$44.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Meribank Biotech Co (ROCO:4724) has a EV-to-EBITDA of 39.40 as of Sep. 14, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Meribank Biotech Co. According to the industry distribution chart, Meribank Biotech Co ranks #314 out of 404 companies in the Biotechnology industry, placing it in the top 77.7%.
Is Meribank Biotech Co's EV-to-EBITDA too high?
Meribank Biotech Co's current EV-to-EBITDA is 39.40. The Biotechnology industry median EV-to-EBITDA is 13.02. Meribank Biotech Co's value of 39.40 is 202.6% above this industry median. Based on the distribution chart, Meribank Biotech Co ranks #314 out of 404 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Meribank Biotech Co has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Meribank Biotech Co's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Meribank Biotech Co ranks #314 out of 404 companies for EV-to-EBITDA. This places Meribank Biotech Co in the lower half of its industry. The industry median EV-to-EBITDA is 13.02. Meribank Biotech Co's value of 39.40 is 202.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.02, based on 404 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Meribank Biotech Co's current EV-to-EBITDA of 39.40 is 202.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Meribank Biotech Co. For the Biotechnology industry, the median EV-to-EBITDA is 13.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Meribank Biotech Co's current EV-to-EBITDA is 39.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Meribank Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Meribank Biotech Co (ROCO:4724) is currently considered Possible Value Trap. The stock's GF Value™ is NT$22.01, compared to a current price of NT$8.95 — trading 59.3% below its estimated fair value. The current EV-to-EBITDA is 39.40 and 202.6% above the Biotechnology industry median of 13.02. Meribank Biotech Co's overall GF Score™ is 45/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Meribank Biotech Co (ROCO:4724), the current EV-to-EBITDA is 39.40 as of Sep. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Meribank Biotech Co (ROCO:4724) Overvalued in 2026?
Based on GuruFocus' analysis, Meribank Biotech Co stock appears to be undervalued.
The current stock price of NT$8.95 is trading 59.3% below its estimated GF Value™ of NT$22.01.
GuruFocus considers Meribank Biotech Co to be Possible Value Trap.
Key valuation signals for ROCO:4724:
EV-to-EBITDA: 39.40
GF Value™: NT$22.01 vs. price of NT$8.95 (59.3% below fair value)
Industry Position: 202.6% above the Biotechnology median (#314 of 404)
No single metric tells the full story. See the ROCO:4724 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Meribank Biotech Co Ltd is engaged in Research and development and sales of new cell drugs and also Umbilical cord blood, placenta and umbilical cord mesenchymal stem cells processing, testing and cryopreservation.
45GF Score
Get the complete analysis for ROCO:4724
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4724 has been successfully added to your 
